Project Grant R01DE034121
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $491,193 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the University of California, San Diego (UCSD) for the project "Engineering Mucin Analogues to Benefit the Mouth Environment." The project aims to create advanced mucin substitutes that closely emulate the physiological functions of natural salivary mucins, in order to develop enhanced artificial saliva...
- This $314,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to gain insights into the evolution of fungal resistance in the oral environment of HIV-positive individuals. The research will leverage an existing patient dataset to: 1) use long-read sequencing to profile the fungal mycobiome in patient saliva and caries samples, and 2) perform longitudinal...
- This $463,530 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121) will support research to investigate the pathogenicity of alcohol-tolerant strains of the fungus Candida albicans in the oral cavity. The research will utilize human oral epithelial cell cultures and an immunosuppressed mouse model of oropharyngeal candidiasis to determine whether alcohol-tolerant C....
- This $164,255 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to develop innovative methacrylate-based dental materials that can inhibit the formation of microbial biofilms to prevent secondary caries. The key objectives are to: (1) synthesize a new 2-aminoimidazole derivative, H10, and generate a methacrylate-based antimicrobial agent containing covalently conjugated...
- The University of Kansas Center for Research Inc. was awarded a $467,008 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), to develop a novel non-invasive treatment for dental caries in children and patients with special needs. The project aims to create a biomimetic peptide-polymer interface that works synergistically with silver diamine fluoride (SDF) to arrest caries progression and...
- This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will provide $460,885 to The Trustees of the University of Pennsylvania to investigate how the interaction between the fungus Candida albicans and the bacteria Streptococcus mutans leads to the initiation and progression of severe early-childhood caries (S-ECC). The research aims to understand how this interkingdom microbial...
- This Project Grant award of $398,000.00 from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will support a study by the ADA Forsyth Institute, Inc. (doing business as The Forsyth Institute) to investigate the synergistic interactions between three key bacterial species - Fusobacterium nucleatum, Actinomyces spp., and Saccharibacteria (TM7) - and their impact on periodontal inflammation in the context of...
- The National Institute of Dental and Craniofacial Research (NIDCR), through the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $406,496 Project Grant to Antixero to develop an extended-duration hyaluronic acid-based oral rinse to provide relief for cancer patients suffering from xerostomia (chronic dry mouth). This innovative solution aims to address the significant unmet need for long-lasting, non-toxic treatments for this debilitating condition, which often...
- The federal Project Grant award of $309,038, issued on August 8, 2025 by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports the development of a novel anti-infective therapy for treating periodontitis. The project aims to develop a first-in-class inhibitor of the "red complex" bacteria (P. gingivalis, T. forsythia, and T. denticola) that are considered the causative agents of periodontitis, a...
- This $431,750 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to decipher the mechanisms by which two proteins, AAFLP-1 and AADCUB, regulate the production of exopolysaccharide (PNAG) in the oral bacterium Aggregatibacter actinomycetemcomitans. The research aims to investigate how these two proteins, which are unique to A. actinomycetemcomitans, independently...
SALIVARY PEPTIDE/PROTEIN-BASED MULTILAYER DENTURE COATINGS FOR CONTROLLING CANDIDA BIOFILM FORMATION AND DENTURE STOMATITIS - PROJECT SUMMARY/ABSTRACT: CANDIDA-ASSOCIATED DENTURE STOMATITIS (CADS), DUE TO CANDIDA COLONIZATION AND BIOFILM FORMATION ON THE DENTURE SURFACE, IS A SIGNIFICANT CLINICAL CONCERN AND AFFECTS UP TO 67% OF DENTURE WEARERS. FUNGAL BIOFILMS SERVE AS A RESERVOIR FOR VARIOUS ORAL BACTERIA THAT CAUSE ORAL HEALTH PROBLEMS AND SYSTEMIC INFECTIONS. CURRENTLY, STRATEGIES FOR CONTROLLING CADS ARE CLINICALLY CHALLENGING AND HAVE HIGH REINFECTION RATES, PARTICULARLY IN ELDERLY AND/OR IMMUNOLOGICALLY- OR MEDICALLY-COMPROMISED PATIENTS. THIS PROPOSAL IS BEING SUBMITTED IN RESPONSE TO NIDCR RFA-DE-24-004 AND AIMS TO USE NATURAL SALIVARY ANTICANDIDAL PEPTIDES/PROTEINS IN MULTILAYER COATINGS ON DENTURES TO CONTROL CADS. WE HAVE PREVIOUSLY DEMONSTRATED THAT COVALENTLY BINDING FUNCTIONAL POLYMERS, SUCH AS POLY(METHACRYLIC ACID) (PMAA), ONTO CONVENTIONAL DENTURES ENHANCES THE BINDING OF CATIONIC ANTICANDIDAL BIOMOLECULES, INCLUDING HISTATIN 5 (H-5), A MAJOR SALIVARY POLYPEPTIDE OF THE HISTATIN FAMILY WITH HIGH ANTICANDIDAL ACTIVITY. THE PMAA FUNCTIONALIZED DENTURE MATERIAL MAINTAINED THE PHYSICAL/MECHANICAL PROPERTIES OF THE ORIGINAL RESIN. WE HAVE FURTHER USED A LAYER-BY- LAYER (LBL) SELF-ASSEMBLY TECHNOLOGY (ALTERNATING THE DEPOSITION OF OPPOSITELY CHARGED POLYELECTROLYTES) BY PAIRING H-5 WITH HYALURONIC ACID (HA), AN ANIONIC UNSULFATED SALIVARY GLYCOSAMINOGLYCAN, TO FORM H-5/HA MULTILAYER COATINGS, RESULTING IN AN INCREASE IN THE H-5 CONTENT ON THE SURFACE OF THE DENTURE MATERIAL. USING H-5 AS THE OUTERMOST LAYER, THE LBL SELF-ASSEMBLED H-5/HA MULTILAYER COATINGS INHIBITED CANDIDA ADHESION AND HAD LONG-LASTING (WEEKS TO MONTHS) ANTICANDIDAL EFFECTS THAT BLOCKED CANDIDA BIOFILM FORMATION. THE LBL COATINGS WERE STABLE AND REMAINED ON THE DENTURE SURFACE AFTER EXTENSIVE MECHANICAL BRUSHING (E.G., >20,000 CYCLES OF BRUSHING). THE LONG-TERM GOAL OF THIS PROJECT IS TO USE NORMAL SALIVARY COMPONENTS AS NATURAL AND SAFE ANTIFUNGAL THERAPEUTICS FOR CONTROLLING CANDIDA BIOFILM FORMATION AND MANAGING CADS. THE MAIN OBJECTIVES OF THIS PROPOSAL ARE TO EVALUATE THE EFFICACY OF SALIVARY ANTICANDIDAL PEPTIDES/PROTEINS IN MULTILAYER COATINGS FOR CONTROLLING CANDIDA BIOFILM FORMATION ON RAT DENTURES AND IN A NOVEL RAT DENTURE STOMATITIS MODEL. THE SPECIFIC AIMS OF THE PROPOSED RESEARCH ARE: (1) TO FABRICATE RAT DENTURES WITH SALIVARY ANTICANDIDAL PEPTIDE/PROTEIN-BASED LBL MULTILAYER COATINGS; (2) TO EVALUATE THE ANTICANDIDAL ACTIVITY AND BIOCOMPATIBILITY OF THE FUNCTIONALIZED AND COATED DENTURES IN VITRO; AND (3) TO EVALUATE THE PRECLINICAL EFFICACY OF THE DENTURES COATED WITH SALIVARY ANTICANDIDAL PEPTIDE/PROTEIN MULTILAYERS IN VITRO AND IN VIVO. IF SUCCESSFUL, THIS NEW DENTURE TECHNOLOGY WILL BE THE FIRST THERAPEUTIC DENTURE USING NATURAL SALIVARY COMPONENTS TO PROVIDE A LONG-TERM BIOFILM-CONTROLLING EFFECTS, PREVENT UNNECESSARY DRUG EXPOSURE, AND MINIMIZE THE RISK OF DEVELOPING CANDIDA RESISTANCE. THESE ANTICANDIDAL TECHNOLOGIES WILL NOT ONLY HAVE A SIGNIFICANT IMPACT ON CLINICAL DENTISTRY BUT MAY ALSO PROVIDE NEW MATERIALS FOR A VARIETY OF MEDICAL DEVICES (E.G., CATHETERS, ENDOTRACHEAL TUBES) AND REDUCE HOSPITAL-ACQUIRED INFECTIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $63.1k | 5/8/25 | ||
| Not listed | $567.6k | 4/3/25 | ||
| Not listed | $567.6k | 4/3/25 | ||
| Not listed | $644.8k | 7/31/24 | ||
| Not listed | $644.8k | 7/31/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
S5025000060534LK1112S | The University Of Texas Health Science Center At San Antonio | Project Grant R01DE034121 | $872.9k | 6/22/25 |